Related Experiment Video
Updated: Apr 24, 2026
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Microvascular and stromal normalization combined with nano-immunotherapy: A synergistic strategy to overcome drug
Fatemeh Mirala1, Farshad Moradi Kashkooli1, M Soltani2
1Department of Mechanical Engineering, K.N. Toosi University of Technology, Tehran, Iran.
Abstract:
Solid tumors like advanced-stage prostate carcinoma pose significant hindrances to therapeutic approaches due to a rich tumor microenvironment (TME) that establishes strong physical and immune resistance to treatment. The TME is defined by a dense, fibrotic stroma and non-functional vasculature, which produce high mechanical stress, high interstitial fluid pressure (IFP), and hypoxia. These properties critically inhibit therapeutic agent penetration and suppress anti-tumor immunity. This review details the mechanistic foundation of such hindrances and discusses the nascent paradigm of TME normalization. This review critically evaluates approaches aimed at stromal normalization, which include anti-cancer stroma cell targeting and extracellular matrix (ECM) degradation, as well as vascular normalization, which involves anti-angiogenic therapy for vessel repair. The unifying hypothesis of this review is that therapeutic efficacy in advanced solid tumors can be significantly enhanced by first restoring key abnormalities of the tumor microenvironment, including vascular dysfunction and stromal stiffness, thereby improving perfusion, reducing hypoxia, and facilitating immune cell and nanoparticle penetration. This microenvironmental normalization creates a transient therapeutic window that can be strategically exploited through nano-immunotherapy. This strategy enhances the penetration of nanoparticles, streamlines immune cell migration, and counteracts immune suppression. Lastly, key clinical issues and future directions include optimal scheduling, predictive markers, and next-generation nanocarriers. This overall strategy offers a combined method to overcome cancer resistance while improving outcomes in difficult-to-treat tumors.
Insights
Normalizing the tumor microenvironment (TME) by addressing stromal stiffness and vascular dysfunction can overcome resistance in solid tumors. This approach enhances drug delivery and immune response, improving treatment outcomes.
Area of Science:
- Oncology
- Cancer Biology
- Nanotechnology
Background:
- Solid tumors, including advanced prostate carcinoma, present therapeutic challenges due to a complex tumor microenvironment (TME).
- The TME features a dense stroma and dysfunctional vasculature, leading to high mechanical stress, interstitial fluid pressure (IFP), and hypoxia.
- These factors impede drug penetration and suppress anti-tumor immunity, contributing to treatment resistance.
Purpose of the Study:
- To review the mechanistic basis of TME-mediated therapeutic resistance in solid tumors.
- To discuss the emerging strategy of TME normalization, focusing on stromal and vascular normalization.
- To evaluate the potential of nano-immunotherapy within a normalized TME for enhanced cancer treatment.
Main Methods:
- Review of existing literature on TME composition and its impact on therapy.
- Critical evaluation of stromal normalization approaches (e.g., targeting stroma cells, ECM degradation).
- Assessment of vascular normalization strategies (e.g., anti-angiogenic therapy).
- Analysis of nano-immunotherapy applications in the context of TME normalization.
Main Results:
- TME normalization strategies aim to restore vascular function and reduce stromal stiffness.
- Restoring TME homeostasis improves drug perfusion, reduces hypoxia, and facilitates immune cell and nanoparticle delivery.
- Nano-immunotherapy, when applied to a normalized TME, enhances nanoparticle penetration, immune cell migration, and counteracts immune suppression.
Conclusions:
- Therapeutic efficacy in advanced solid tumors can be significantly improved by normalizing the TME.
- TME normalization creates a therapeutic window exploitable by nano-immunotherapy.
- Future research should focus on clinical implementation, including scheduling, predictive markers, and advanced nanocarriers for optimal outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...